Group 1 - The company provided guarantees totaling 74.32 million yuan for its subsidiaries to support their production and business development needs, while also releasing guarantees amounting to 25.70 million yuan [2][3] - The company has a total guarantee limit of up to 7 billion yuan for the year 2025, which was approved in the shareholders' meeting [3][4] - The guarantees are deemed necessary and reasonable as they align with the company's overall interests and development strategy, with the subsidiaries being under the company's absolute control [4][5] Group 2 - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amounted to 2.70 billion yuan, representing 35.46% of the company's latest audited net assets [6] - The company does not have any overdue guarantees and has not provided guarantees for its controlling shareholders or related parties [6] Group 3 - The controlling shareholder, Mr. Zhu Chaoyang, holds 101,032,795 shares, accounting for 25.44% of the total share capital, and has pledged 28,660,000 shares, which is 28.37% of his holdings [9][10] - The pledge of shares has been extended, with the repurchase date set for August 21, 2025, and no new financing arrangements are involved [10][11] - Mr. Zhu's personal credit status is good, and he has the ability to repay, with no current risk of forced liquidation [12]

证券日报网讯 8月8日晚间，柳药集团发布公告称，2025年7月，为支持广西柳药集团股份有限公司下属 控股子公司的生产经营和业务发展需要，公司就下属控股子公司向银行申请综合授信等事项合计新增 7，432.48万元的担保，同时解除担保金额合计2，570.01万元。截至本公告日，公司及下属控股子公司 对外担保总额为270，383.14万元，占公司最近一期经审计净资产的35.46%，其中公司对下属控股子公 司提供的担保总额为254，852.31万元，占公司最近一期经审计净资产的33.43%。 （文章来源：证券日报） ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-060 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于控股股东部分股份解除质押及质押延期购回的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 广西柳药集团股份有限公司（以下简称"公司"）控股股东暨实际控制人 朱朝阳先生持有本公司股份 101,032,795 股，占公司目前总股本的 25.44%。本次 解除质押及质押延期购回后，朱朝阳先生累计质押公司股份 28,660,000 股，占其 所持有公司股份的 28.37%，占公司目前总股本的 7.22%。前述质押股份将质押 延期购回业务。 近日，公司接到控股股东朱朝阳先生关于将其所持部分公司股份办理解除质 押及质押延期购回业务的通知。具体情况如下： （www.sse.com.cn）及指定媒体上披露的相关公告（公告编号：2023-088、 2024-079）。 一、本次股份解除质押基本情况 ...

广西柳药集团股份有限公司 关于为下属控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 广西南宁柳药药业有限公司（简称"南宁柳药"） | | --- | --- | --- | --- | | | 本次担保金额 | 1,432.48 | 万元 | | 担保 对象一 | 实际为其提供的担保余额 | 155,862.31 | 万元（含本次） | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | □不适用：_________ | | 担保 | 被担保人名称 | | 广西仙茱制药有限公司（简称"仙茱制药"） | | | 本次担保金额 | 3,000.00 | 万元 | | 对象二 | 实际为其提供的担保余额 | 8,000.00 | 万元（含本次） | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担 ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary having a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1-2 million yuan, and 3% above 2 million yuan [2] - The top three highest-paid secretaries are from Shanghai Pharmaceuticals, Run Da Medical, and China National Pharmaceutical Group, with salaries of 2.0373 million yuan, 1.6242 million yuan, and 1.2 million yuan respectively [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary having a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1 million-2 million yuan, and 3% earning over 2 million yuan [2] - The top three highest-paid secretaries are Zhong Tao from Shanghai Pharmaceuticals with 2.0373 million yuan, Zhang Chengxu from Run Da Medical with 1.6242 million yuan, and Luo Lichun from China National Pharmaceutical with 1.2 million yuan [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603368 证券简称：柳药集团 公告编号：2025-058 转债代码：113563 转债简称：柳药转债 广西柳药集团股份有限公司 关于以集中竞价交易方式首次回购股份的公告 一、回购股份的基本情况 广西柳药集团股份有限公司（以下简称"公司"）于2025年7月25日召开第五届董事会第二十七次会议， 审议通过了《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金和自筹资金通过 集中竞价交易方式回购部分公司A股股份，在未来适宜时机用于实施股权激励及/或员工持股计划。本次 回购资金总额不低于人民币10,000万元（含），不超过人民币20,000万元（含）；回购价格上限不超过 人民币25.70元/股（含）；回购期限为自董事会审议通过本次回购方案之日起不超过12个月。具体内容 详见公司分别于2025年7月26日、2025年8月5日在上海证券交易所网站（www.sse.com.cn）披露的《关 于以集中竞价交易方式回购股份方案的公告》（公告编号：2025-053）、《关于以集中竞价交易方式回 购股份的回购报告书》（公告编号：2025-056）。 二、 ...

Group 1 - As of August 6, 2025, Liu Pharmaceutical Group's stock price closed at 18.33 yuan, down 0.21 yuan or 1.13% from the previous trading day [1] - The company is a leading pharmaceutical enterprise in Guangxi, with its main business segments including wholesale (78.89% of revenue), retail (15.15%), and industrial (5.49%) [1] - On the evening of August 6, the company announced its first share buyback of 544,500 shares, representing 0.14% of total equity, with a buyback amount of 9.9828 million yuan at a price range of 18.29 to 18.36 yuan [1] Group 2 - The company plans to use 100 to 200 million yuan for share buybacks, with a maximum buyback price of 25.70 yuan per share and a buyback period of 12 months [1] - On August 6, there was a net outflow of 32.8016 million yuan in main funds, with a cumulative net outflow of 2.7208 million yuan over the past five days [1]

Group 1 - Jerry Holdings reported a net profit of 1.241 billion yuan for the first half of 2025, an increase of 14.04% year-on-year, with total revenue reaching 6.901 billion yuan, up 39.21% year-on-year [1] - Tian Tan Biological announced a net profit of 633 million yuan for the first half of 2025, a decrease of 12.88% year-on-year, with total revenue of 3.110 billion yuan, an increase of 9.47% year-on-year [2] - Shunbo Alloy achieved a net profit of 177 million yuan for the first half of 2025, a significant increase of 110.56% year-on-year, with total revenue of 7.126 billion yuan, up 11.75% year-on-year [7] Group 2 - Dashi Intelligent signed a contract for the Jingpai Building smart project with a total contract value of 34.06 million yuan, accounting for 1.07% of the company's audited revenue for 2024 [3] - Maglev Technology plans to invest 700 million yuan to establish a research and production base for maglev compressors, aiming to optimize product structure and enhance production capacity [4] - Koweil received government subsidies totaling 5.502 million yuan, which are expected to positively impact the company's profits for 2025 [5] Group 3 - Pengding Holdings reported a consolidated revenue of 3.002 billion yuan for July 2025, an increase of 12.28% compared to the same period last year [9] - Liuyou Group repurchased 544,500 shares at a price range of 18.29 to 18.36 yuan per share, totaling approximately 9.9828 million yuan [10] - Jin Xin Nong reported a sales revenue of 96.731 million yuan from pig sales in July 2025, with a total of 79,400 pigs sold [12] Group 4 - Jiangsu Huachen plans to use up to 70 million yuan of idle raised funds for cash management, investing in safe and liquid financial products [13] - Gongtong Pharmaceutical's subsidiary intends to purchase assets from an affiliate for 16.57 million yuan to build a wastewater treatment facility [15] - Tian Shi Li appointed Wang Yimin as the vice general manager, effective immediately [16] Group 5 - Zhejiang Yongqiang established a subsidiary in Indonesia with a registered capital of 230 billion Indonesian rupiah, focusing on overseas capacity investment and international trade [18] - Wangli Security received three invention patents, enhancing its product portfolio in security locks [20] - Shennong Group reported a sales revenue of 327 million yuan from pig sales in July 2025, with an average selling price of 14.73 yuan per kilogram [21] Group 6 - Dize Pharmaceutical's product DZD8586 received fast track designation from the FDA for treating relapsed refractory chronic lymphocytic leukemia [23] - Daqin Railway reported a cargo transportation volume of 31.79 million tons in July 2025, a year-on-year increase of 5.40% [24] - Xin Hongye's subsidiary won a bid for a nuclear-grade cable procurement project worth 81.58 million yuan [26] Group 7 - Hainan Hengbo established a wholly-owned subsidiary with a registered capital of 50 million yuan, focusing on technology services and new material technology research [26] - Changhong Huayi reported a net profit of 257 million yuan for the first half of 2025, an increase of 13.42% year-on-year, with total revenue of 6.628 billion yuan [27] - Haiguang Information achieved a net profit of 1.201 billion yuan for the first half of 2025, an increase of 40.78% year-on-year, with total revenue of 5.464 billion yuan [28] Group 8 - Dongmu Co. reported a net profit of 261 million yuan for the first half of 2025, an increase of 37.61% year-on-year, with total revenue of 2.930 billion yuan [29] - Hanma Technology announced the resignation of its executive vice president due to personal reasons [30] - Guangge Technology's shareholders plan to reduce their holdings by up to 4.04% of the company's shares [31] Group 9 - *ST Energy's subsidiary won a bid for an independent energy storage project with a total bid price of 320 million yuan for design and 301 million yuan for construction [32] - Chipeng Micro plans to reduce its holdings by up to 2% of the company's shares due to personal financial needs [33] - Ancar Detection announced a change in its controlling shareholder to Silicon Technology, with stock resuming trading [35] Group 10 - Dahao Technology's vice president is temporarily unable to perform duties due to health reasons [36] - Sanjiang Shopping's cooperation agreement with Hema will not be renewed after its expiration in March 2026 [37] - Huisheng Biological reported a net profit of 117 million yuan for the first half of 2025, a year-on-year increase of 325.88% [38] Group 11 - Dongshan Precision plans to increase capital in its subsidiary by 3.5 billion USD to support high-end PCB projects [39] - Yunnan Copper's subsidiary's bankruptcy liquidation application has been accepted by the court due to resource depletion [40] - Shanghai Bank's board member and chairman's qualifications have been approved by regulatory authorities [41] Group 12 - Junwei Electronics plans to acquire 100% of Flat Electronics Co., Ltd. for 2.6 billion yen to enter the film resistor market [42] - Daodaoquan's controlling shareholder plans to increase its stake in the company by 50 million to 100 million yuan [43] - Yinglian Co.'s subsidiary signed a strategic cooperation agreement with a well-known cylindrical battery company [45] Group 13 - Debang Technology's state integrated circuit fund plans to reduce its holdings by up to 3% of the company's shares [47] - Tianyi New Materials plans to sell part of its subsidiary's assets for 51.4 million yuan to improve cash flow [49] - Rongtai Co. intends to acquire 51% of Zhongshan Aoduo for 288 million yuan [51]

Group 1 - The company announced a share repurchase plan with a total expected amount between 100 million and 200 million RMB [1][2] - The repurchase period is set from July 25, 2025, to July 24, 2026 [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Group 2 - As of now, the company has repurchased a total of 544,500 shares, representing 0.14% of the total share capital [2] - The total amount spent on the repurchase so far is 9.9828 million RMB, with a price range of 18.29 to 18.36 RMB per share [2] - The company will continue to make repurchase decisions based on market conditions and will fulfill information disclosure obligations [2]